Get the Stockscreener App
6.34
7.82%
0.46
After Hours:
6.51
0.17
+2.68%
Terns Pharmaceuticals Inc stock is traded at $6.34, with a volume of 1.93M.
It is up +7.82% in the last 24 hours and down -4.95% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
See More
Previous Close:
$5.88
Open:
$5.97
24h Volume:
1.93M
Relative Volume:
0.99
Market Cap:
$516.85M
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-4.9147
EPS:
-1.29
Net Cash Flow:
$-79.09M
1W Performance:
+13.21%
1M Performance:
-4.95%
6M Performance:
+5.67%
1Y Performance:
+64.25%
1-Day Range:
$5.82
$6.37
1-Week Range:
$5.46
$6.37
52-Week Range:
$3.86
$11.40
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
6.34 | 516.85M | 0 | -95.90M | -79.09M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Terns Pharmaceuticals (TERN) Stock Surges Over 5% Amid Biotech S - GuruFocus.com
Companies To Watch: Terns Pharmaceuticals - Life Science Leader Magazine
Terns Pharmaceuticals' SWOT analysis: stock poised for key data readouts - Investing.com
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Telemark Asset Management LLC Acquires Shares of 300,000 Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - MarketBeat
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
104,535 Shares in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Purchased by Quest Partners LLC - MarketBeat
Terns Pharmaceuticals (TERN) Stock Drops Over 5% Amidst Mixed In - GuruFocus.com
Terns Pharmaceuticals appoints new board member - Investing.com
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors - GlobeNewswire
Terns Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Terns Pharmaceuticals Appoints Heather Turner to Board - TipRanks
Terns Pharmaceuticals (NASDAQ:TERN) Stock Price Down 8.7%Should You Sell? - MarketBeat
Steven Cohen's Strategic Acquisition in Terns Pharmaceuticals Inc - GuruFocus.com
Insiders Re-Evaluate Their US$5.05m Stock Purchase As Terns Pharmaceuticals Falls To US$556m - Simply Wall St
Research Analysts Issue Forecasts for TERN FY2024 Earnings - Defense World
HC Wainwright Has Bullish Forecast for TERN FY2024 Earnings - MarketBeat
Q1 Earnings Forecast for TERN Issued By HC Wainwright - MarketBeat
We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth - Yahoo Finance
Terns Pharmaceuticals Reports Q3 Progress and Financials - TipRanks
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Terns Pharmaceuticals Inc Reports Q3 2024 Net Loss Per Share of $0.28, Cash Position Strengthened to $372.8 Million - GuruFocus.com
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates - GlobeNewswire
Creative Planning Purchases 5,409 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences - The Manila Times
Terns Pharmaceuticals to Present at UBS and Jefferies Healthcare Conferences in November | TERN Stock News - StockTitan
Where are the Opportunities in (TERN) - Stock Traders Daily
This small-cap stock is expected to take off — if its weight-loss pill trial succeeds - MSN
Terns Surges 29.6% in Three Months: Will the Momentum Continue? - MSN
Critical Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) vs. Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Price Target at $15.90 - Defense World
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Oppenheimer initiates Terns Pharmaceuticals stock at Outperform, sees 150% upside - Investing.com Australia
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $15.90 Average Target Price from Analysts - MarketBeat
Terns Pharmaceuticals (NASDAQ:TERN) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Objective long/short (TERN) Report - Stock Traders Daily
Bleakley Financial Group LLC Purchases 2,751 Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
SG Americas Securities LLC Buys Shares of 23,810 Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns identifies new GLP-1R agonists - BioWorld Online
Financial Comparison: Oculis (NASDAQ:OCS) and Terns Pharmaceuticals (NASDAQ:TERN) - Defense World
Will The LIFT Data Boost Terns Stock? - RTTNews
Terns Pharmaceuticals: Another Potential GLP-1 Entrant (NASDAQ:TERN) - Seeking Alpha
Top investors say Terns Pharmaceuticals Inc (TERN) ticks everything they need - SETE News
(TERN) Technical Pivots with Risk Controls - Stock Traders Daily
A stock that deserves closer examination: Terns Pharmaceuticals Inc (TERN) - US Post News
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Short Interest Update - MarketBeat
Mizuho gives a Buy recommendation for Terns Pharmaceuticals Inc (TERN) - Knox Daily
Why Terns Pharmaceuticals Inc Stock Might Make Sense If Bought Today - Stocks Register
Marshall Wace LLP Decreases Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) - Defense World
Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Shares Sold by Marshall Wace LLP - MarketBeat
Institutional investors in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) lost 9.7% last week but have reaped the benefits of longer-term growth - Simply Wall St
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):